Minimal information for studies of extracellular vesicles (MISEV2023): From basic to advanced approaches
- PMID: 38326288
- PMCID: PMC10850029
- DOI: 10.1002/jev2.12404
Minimal information for studies of extracellular vesicles (MISEV2023): From basic to advanced approaches
Erratum in
-
Correction to "Minimal information for studies of extracellular vesicles (MISEV2023): From basic to advanced approaches".J Extracell Vesicles. 2024 May;13(5):e12451. doi: 10.1002/jev2.12451. J Extracell Vesicles. 2024. PMID: 38726651 Free PMC article. No abstract available.
Abstract
Extracellular vesicles (EVs), through their complex cargo, can reflect the state of their cell of origin and change the functions and phenotypes of other cells. These features indicate strong biomarker and therapeutic potential and have generated broad interest, as evidenced by the steady year-on-year increase in the numbers of scientific publications about EVs. Important advances have been made in EV metrology and in understanding and applying EV biology. However, hurdles remain to realising the potential of EVs in domains ranging from basic biology to clinical applications due to challenges in EV nomenclature, separation from non-vesicular extracellular particles, characterisation and functional studies. To address the challenges and opportunities in this rapidly evolving field, the International Society for Extracellular Vesicles (ISEV) updates its 'Minimal Information for Studies of Extracellular Vesicles', which was first published in 2014 and then in 2018 as MISEV2014 and MISEV2018, respectively. The goal of the current document, MISEV2023, is to provide researchers with an updated snapshot of available approaches and their advantages and limitations for production, separation and characterisation of EVs from multiple sources, including cell culture, body fluids and solid tissues. In addition to presenting the latest state of the art in basic principles of EV research, this document also covers advanced techniques and approaches that are currently expanding the boundaries of the field. MISEV2023 also includes new sections on EV release and uptake and a brief discussion of in vivo approaches to study EVs. Compiling feedback from ISEV expert task forces and more than 1000 researchers, this document conveys the current state of EV research to facilitate robust scientific discoveries and move the field forward even more rapidly.
Keywords: MISEV; ectosomes; exosomes; extracellular particles; extracellular vesicles; guidelines; microparticles; microvesicles; minimal information requirements; reproducibility; rigor; standardisation.
© 2024 The Authors. Journal of Extracellular Vesicles published by Wiley Periodicals, LLC on behalf of the International Society for Extracellular Vesicles.
Conflict of interest statement
Pierre Arsène is CEO of Mursla Ltd. and Chair of Exosla Ltd; Antonella Bongiovanni has filed the patent (PCT/EP2020/086622) related to microalgal‐derived extracellular vesicles and is co‐founder and CEO of the spin‐off company EVEBiofactory srl; Paul C Boutros sits on the scientific advisory boards of Sage Bionetworks, Intersect Diagnostics Inc and BioSymetrics Inc; Xandra O Breakefield is Scientific Advisor for Evox and MGB‐Cannon; Edit I Buzas is a member of the Scientific Advisory Boards of Sphere Gene Therapeutics Inc (Boston, MA, USA) and ReNeuron (UK); David RF Carter is an Evox Therapeutics Ltd, employee and stock option holder; Anna Cifuentes‐Rius was employed by Exopharm Ltd when the survey was conducted ACR is a shareholder of Exopharm Ltd; Rossella Crescitelli has developed multiple EV‐associated patents for putative clinical utilisation and they own equity in Exocure Sweden AB; Andrew Devitt is Chief Technical Officer, co‐founder, and director of EVolution Therapeutics; Erez Eitan works and has equity in NeuroDex, a company that develops EV‐based diagnostics; Samir EL Andaloussi is co‐founder of Evox Therapeutics; Ludwig Ermann Lundberg is an employee of BioGaia; Susanne Gabrielsson has a patent on B cell derived EVs in immune therapy and is part of the Scientific Advisory Board of Anjarium Biosciences; Ernesto Gargiulo is a medical writer at Novo Nordisk A/S; Bernd Giebel is a member of the Scientific Advisory Boards of Mursla Ltd, ReNeuron, and PLBioscience and is the founding director of Exosla Ltd; André Görgens is a consultant for and has equity interest in Evox Therapeutics (Oxford, UK) and is an inventor on several patent applications and patents related to EV isolation, modification, and analytics; Ahmed GE Ibrahim owns stock in Capricor Therapeutics; Marzena Kurzawa‐Akanbi Kurzawa‐Akanbi is an academic founder and Chief Scientific Officer at ESP Diagnostics Limited; Quentin Lubart is an employee of Abbelight (Cachan, France), which constructs and sells super‐resolution microscopes to characterize EVs; Fabrice Lucien receives consulting fees from Mursla Bio and Early is Good; Elisa Lázaro‐Ibáñez is employed by AstraZeneca R&D; Jan Lötvall is co‐founder of two companies aiming to develop EV‐based therapeutics, Exocure Sweden AB and Nexo Therapeutics AB, has been or is a scientific consultant for NanoSight, Clara Biotech and ExoCoBio, and was Editor‐in‐Chief of the Journal of Extracellular Vesicles during the development and publication of MISEV2023; Eduardo Marbán has founder's equity in Capricor Therapeutics Inc; Maurizio Muraca is a consultant for EXO Biologics (Liège, Belgium); Irina Nazarenko is a scientific adviser of CapCO Bio GmbH; D Michiel Pegtel has research funding from Takeda, Amgen, Abbvie, and Gilead, is an advisor of Y2Y BV, and has equity in Y2Y BV; Janusz Rak is inventor on a patent on oncogene‐carrying EVs that is licensed to NXPharmaGene; Gregory E Rice is Chief Scientific Officer, Inoviq Ltd; Andrew Rowland is a recipient of investigator‐initiated research funding outside of the scope of this publication from AstraZeneca, Boehringer Ingelheim, and Pfizer and is a recipient of speakers fees from Boehringer Ingelheim and Genentech; Susmita Sahoo performs research funded by Evox Therapeutics; Randy Schekman is a member of the Scientific Advisory Boards of companies involved in the analysis and diagnostic/therapeutic application of various forms of synthetic or native extracellular vesicles in diagnostics: Sail (formerly Senda) Biomedicines, Invaio Sciences, Mercy BioAnalytics, and Esperovax; Raymond M Schiffelers is CSO of Excytex bv; Johan Skog is an employee of Bio‐Techne and an inventor on patents for exosome isolation and analysis; Vera A Tang is a consultant for Beckman Coulter on small particle flow cytometry; Clotilde Théry is an inventor on a submitted patent on therapeutic use of EVs; Edwin van der Pol is cofounder and shareholder of Exometry, Amsterdam, The Netherlands; Joshua A Welsh is an inventor on patents and patent applications related to EV analysis; Oscar PB Wiklander has stock options with Evox Therapeutics; Kenneth W Witwer is or has been an advisory board member of ShiftBio, Exopharm, NeuroDex, NovaDip, and ReNeuron; holds NeuroDex options; privately consults as Kenneth Witwer Consulting; and conducts research under a sponsored research agreement with Ionis Pharmaceuticals.
Figures
References
-
- Aalberts, M. , van Dissel‐Emiliani, F. M. , van Adrichem, N. P. , van Wijnen, M. , Wauben, M. H. , Stout, T. A. , & Stoorvogel, W. (2012). Identification of distinct populations of prostasomes that differentially express prostate stem cell antigen, annexin A1, and GLIPR2 in humans. Biology of Reproduction, 86, 82. - PubMed
-
- Abbatiello, S. E. , Mani, D. R. , Schilling, B. , Maclean, B. , Zimmerman, L. J. , Feng, X. , Cusack, M. P. , Sedransk, N. , Hall, S. C. , Addona, T. , Allen, S. , Dodder, N. G. , Ghosh, M. , Held, J. M. , Hedrick, V. , Inerowicz, H. D. , Jackson, A. , Keshishian, H. , Kim, J. W. , … Carr, S. A. (2013). Design, implementation and multisite evaluation of a system suitability protocol for the quantitative assessment of instrument performance in liquid chromatography‐multiple reaction monitoring‐MS (LC‐MRM‐MS). Molecular & Cellular Proteomics, 12, 2623–2639. - PMC - PubMed
-
- Aebersold, R. , & Mann, M. (2003). Mass spectrometry‐based proteomics. Nature, 422, 198–207. - PubMed
MeSH terms
Substances
Grants and funding
- P01 CA019014/CA/NCI NIH HHS/United States
- T32 CA079443/CA/NCI NIH HHS/United States
- K99 EB033857/EB/NIBIB NIH HHS/United States
- MR/R025096/1/MRC_/Medical Research Council/United Kingdom
- R01 GM138778/GM/NIGMS NIH HHS/United States
- R35 GM149203/GM/NIGMS NIH HHS/United States
- R01 NS103967/NS/NINDS NIH HHS/United States
- R01 GM148708/GM/NIGMS NIH HHS/United States
- U01 CA224276/CA/NCI NIH HHS/United States
- R35 HL150807/HL/NHLBI NIH HHS/United States
- MR/S009426/1/MRC_/Medical Research Council/United Kingdom
- R01 DK136511/DK/NIDDK NIH HHS/United States
- R01 CA206458/CA/NCI NIH HHS/United States
- R01 AI168142/AI/NIAID NIH HHS/United States
- R01 CA249424/CA/NCI NIH HHS/United States
- R01 AI174273/AI/NIAID NIH HHS/United States
- R01 CA218500/CA/NCI NIH HHS/United States
- R01 MH134389/MH/NIMH NIH HHS/United States
- R01 DA047807/DA/NIDA NIH HHS/United States
- P30 DK058404/DK/NIDDK NIH HHS/United States
- R35 GM136421/GM/NIGMS NIH HHS/United States
- R21 EY035425/EY/NEI NIH HHS/United States
- L30 DE029070/DE/NIDCR NIH HHS/United States
- R01 EY034193/EY/NEI NIH HHS/United States
- FS/IBSRF/22/25110/BHF_/British Heart Foundation/United Kingdom
- R33 MH118164/MH/NIMH NIH HHS/United States
- T32 HL007317/HL/NHLBI NIH HHS/United States
- R01 HL144089/HL/NHLBI NIH HHS/United States
- UH3 TR002881/TR/NCATS NIH HHS/United States
- UH3 TR002884/TR/NCATS NIH HHS/United States
- K99 MH126950/MH/NIMH NIH HHS/United States
- R35 GM151259/GM/NIGMS NIH HHS/United States
- K22 CA282019/CA/NCI NIH HHS/United States
- P01 CA229123/CA/NCI NIH HHS/United States
- R21 EY033057/EY/NEI NIH HHS/United States
- P20 GM113109/GM/NIGMS NIH HHS/United States
- R01 AI144997/AI/NIAID NIH HHS/United States
- U18 TR003807/TR/NCATS NIH HHS/United States
- UH3 CA241694/CA/NCI NIH HHS/United States
- DP2 HL152426/HL/NHLBI NIH HHS/United States
- R56 EY034193/EY/NEI NIH HHS/United States
- RF1 AG059392/AG/NIA NIH HHS/United States
- P41 EB024495/EB/NIBIB NIH HHS/United States
- R01 AR072735/AR/NIAMS NIH HHS/United States
- R01 AI158749/AI/NIAID NIH HHS/United States
- R01 AG081807/AG/NIA NIH HHS/United States
- R01 CA249684/CA/NCI NIH HHS/United States
- R00 CA277242/CA/NCI NIH HHS/United States
- R01 CA270251/CA/NCI NIH HHS/United States
- K99 CA277242/CA/NCI NIH HHS/United States
- L30 MH131119/MH/NIMH NIH HHS/United States
- UH3 TR002886/TR/NCATS NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous
